Cerebrolysin for Stroke and TBI Recovery

The evidence base in plain English

Cerebrolysin has more human RCT evidence behind it than almost any peptide we cover. The Cerebrolysin and Recovery After Stroke (CARS) trials, run in Eastern Europe and published in Stroke, randomized acute ischemic stroke patients to 30mL daily IV (intravenous - delivered through a vein, like a hospital drip) for 21 days plus standard rehab versus placebo plus standard rehab. The drug-treated group showed a statistically significant improvement on the Action Research Arm Test at day 90, with a number-needed-to-treat of 7.1 for clinically relevant early improvement on the NIH Stroke Scale (PMID 26564102 - Muresanu et al. 2016).

The CAPTAIN trial series tested the same protocol in moderate-to-severe TBI. The pooled meta-analysis of CAPTAIN I and CAPTAIN II (185 patients combined) showed a small-to-medium effect size in favor of Cerebrolysin at day 30 and day 90, with safety profiles comparable to placebo (PMID 33620612 - Poon et al. 2020).

A 2018 meta-analysis of nine RCTs in early post-stroke recovery (n = 1,879) confirmed the safety signal and the modest efficacy signal across studies (Bornstein et al. 2018, BMC Neurology).

Real talk: the effect size is modest, not transformative. Cerebrolysin is an add-on to rehab, not a replacement for it. It improves the trajectory; it does not rewrite the outcome.

Week 0: the doctor conversation

The right doctor here is a neurologist or a physiatrist (a physical-medicine-and-rehabilitation specialist) who has either prescribed Cerebrolysin before, or is willing to read the CARS and CAPTAIN papers before prescribing. A general practitioner is the wrong starting point unless they refer up.

Three questions for the appointment:

• Are you familiar with Cerebrolysin and the CARS / CAPTAIN trial data? A doctor who has not heard of it is not a no - they are an unknown. Send them the links above and ask them to review.
• Will you write a script for a 21-day cycle? The dose for acute stroke recovery is 30mL IV daily for 21 days; for maintenance cycles months out from the event, 10 to 30mL IV or IM (intramuscular - injected into a muscle, like a flu shot) daily for 10 to 21 days, repeating every 3 to 6 months. Your doctor decides which protocol fits your case.
• How will we administer it? IV daily for 21 days is a non-trivial logistics ask. Some infusion centers, integrative-medicine clinics, and longevity clinics in the US will administer it if the patient brings the medication and a script. A home health nurse is another path. Ask the doctor to coordinate with whoever will run the line.

If they refuse - that is a defensible position. Cerebrolysin is not FDA-approved and many neurologists will not prescribe outside the US labeled drugs. Thank them and find a second opinion through a longevity clinic or peptide-experienced telehealth provider.

Week 1: the sourcing reality

Cerebrolysin is manufactured by Ever Neuro Pharma in Austria. It comes in 5mL, 10mL, and 30mL ampules (sealed glass vials). The brand-name product is the same molecule regardless of which country dispenses it.

The legitimate paths in 2026:

• International pharmacy with US prescription. Several Mexico-based, EU-based, and India-based pharmacies will dispense Cerebrolysin against a valid US prescription and ship to the US. Cost runs roughly $4 to $10 per 5mL ampule. A 21-day course at 30mL daily is 21 ampules of 30mL, or 126 ampules of 5mL. Total cost: typically $400 to $1,200 per cycle, plus shipping.
• Cross-border travel. Some patients fly to Mexico or Eastern Europe for a 3-week clinic-administered course. This is the standard path for patients who want everything handled in one place. Cost varies widely.
• Longevity clinic with international supply chain. A handful of US longevity clinics stock Cerebrolysin and administer it on site. They are expensive but legitimate.
• Skip: Anyone selling "Cerebrolysin" through a research peptide vendor without ampules, a manufacturer, and a batch number on the box. The drug is a complex peptide mixture - you cannot fake it credibly through a research vendor.

Storage: refrigerated at 36 to 46 degrees Fahrenheit, protected from light, until administration. Each ampule is single-use.

Weeks 2-4: the 21-day cycle

The protocol used in CARS-1, CARS-2, and CAPTAIN was identical:

• 30mL Cerebrolysin diluted in 100 to 250mL of saline, infused IV over 15 to 60 minutes, once daily for 21 consecutive days. Maintenance cycles months out from the event sometimes use 10mL daily by IM injection if IV access is impractical, but the trial evidence is strongest at the 30mL IV dose.
• Pair with standardized rehab. The CARS protocol explicitly required a structured rehab program initiated within 72 hours of stroke onset, alongside the infusions. Cerebrolysin without rehab is not the protocol that was studied.
• Log function daily. For stroke recovery, track the Action Research Arm Test or whatever functional scale your rehab team uses. For TBI, track Glasgow Outcome Scale-Extended or your team's preferred cognitive battery. Subjective improvement reports are not the metric - the clinical scales are.
• Reassess at day 30 and day 90. The CARS data showed effect sizes that grew between day 30 and day 90. Do not judge the protocol at day 14.
• Repeat cycles every 3 to 6 months if you and your doctor agree the first cycle produced measurable benefit and you are still inside a recovery trajectory. Open-ended continuous use is not what was studied.

What success looks like

For acute stroke (first cycle within 72 hours of event), the evidence supports a measurable improvement in motor function and stroke-scale scores at day 30 and day 90 versus what your rehab team would have predicted from rehab alone. The number-needed-to-treat for clinically relevant early NIHSS improvement was 7.1 in CARS - meaning roughly one in seven patients shows a clinically meaningful early benefit from the drug that they would not have shown on rehab alone.

For TBI, expect a small-to-medium effect on cognitive recovery, anxiety, and depression scores at day 30 and day 90, again as add-on to standard rehab. The CAPTAIN II analysis specifically showed signal on anxiety, depression, and cognition at day 90 (Onose et al. 2022).

If your rehab team sees no measurable benefit at day 90, the maintenance cycles are probably not warranted. Save the cost.

What to skip

• Research-peptide-vendor "Cerebrolysin" sold as a powder for reconstitution. The real drug is a liquid mixture of low-molecular-weight neuropeptides, not a single reconstitutable powder. If it does not arrive as Ever Neuro Pharma ampules from Austria, it is not Cerebrolysin.
• IM injection alone for acute stroke. The CARS evidence was IV at 30mL daily. IM is the maintenance-cycle alternative once you are months out from the event, not the acute-stroke protocol.
• Open-ended continuous use. The trials studied 21-day cycles repeated at 3-to-6-month intervals. Daily use for years on end is not what was studied and is not what the safety data covers.
• Combining Cerebrolysin with high-dose nootropic stacks during the cycle. Add one variable at a time. If the cycle works, you want to know it was the cycle.

Subscribe to the dispatch

The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Broken down for normal humans.

Subscribe free